Guyana vs Trinidad and Tobago: Prevalence rate of hypertension in women aged 30-79
Guyana
41.8
in 2019
Trinidad and Tobago
41.6
in 2019
Guyana rank
53rd
Trinidad and Tobago rank
56th
Prevalence rate of hypertension in women aged 30-79 over time
- Guyana
- Trinidad and Tobago
How they compare
Guyana currently reports 41.8 against 41.6 in Trinidad and Tobago, a difference of 0.2.
Across all 30 years both countries report, Guyana has been ahead every year.
Guyana ranks 53rd and Trinidad and Tobago ranks 56th of 195 countries.
Guyana has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Guyana | Trinidad and Tobago | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 36.74 | 33.61 | 3.13 | Guyana |
| 2000s | 39.04 | 36.12 | 2.92 | Guyana |
| 2010s | 41.34 | 40.29 | 1.05 | Guyana |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence rate of hypertension in women aged 30-79, Guyana or Trinidad and Tobago?
- Guyana, at 41.8 against 41.6 in Trinidad and Tobago as of 2019.
- What is the difference in prevalence rate of hypertension in women aged 30-79 between Guyana and Trinidad and Tobago?
- 0.2, with Guyana ahead.
- How many years of comparable data are there for Guyana and Trinidad and Tobago?
- 30 years are reported by both, from 1990 to 2019.
- How do Guyana and Trinidad and Tobago rank globally for prevalence rate of hypertension in women aged 30-79?
- Guyana ranks 53rd and Trinidad and Tobago ranks 56th of 195 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Prevalence rate of hypertension in women aged 30-79. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated share of female population with hypertension, based on population representative surveys and statistical modeling. Hypertension is a risk factor for chronic complications, including cardiovascular disease, and premature death.